Sanofi licenses next-gen radioligand cancer treatment tech from RadioMedix and Orano Med.

Sanofi has entered a licensing agreement with RadioMedix and Orano Med to develop a next-generation radioligand medicine aimed at treating rare cancers. This collaboration seeks to advance innovative treatment options for patients facing these challenging conditions.